Welcome to our dedicated page for Prothena SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotechnology filing packed with clinical data tables and milestone accounting notes can feel daunting. Prothena鈥檚 SEC documents are no exception鈥攖rial updates, R&D burn rates, and partnership revenue estimates are buried across hundreds of pages. If you have ever searched for 鈥淧rothena SEC filings explained simply鈥� or struggled to trace insider sales before a data readout, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries translate Prothena quarterly earnings report 10-Q filing details into clear language, flag key cash-runway metrics, and link every risk factor to its clinical program. Need 鈥淧rothena insider trading Form 4 transactions鈥� or 鈥淧rothena executive stock transactions Form 4鈥� alerts? We deliver them in real-time, alongside expert context. From a single dashboard you鈥檒l also find the Prothena annual report 10-K simplified, 鈥淧rothena proxy statement executive compensation鈥� tables highlighted, and each 鈥淧rothena 8-K material events explained鈥� within minutes of hitting EDGAR.
Whether you monitor biologics pipeline milestones or compare quarter-over-quarter R&D expenses, our platform keeps every document at your fingertips:
- AG真人官方-time updates the moment Prothena Form 4 insider transactions hit the tape
- AI summaries that clarify immunotherapy terminology and clinical-stage accounting
- Side-by-side 鈥淧rothena earnings report filing analysis鈥� for trend spotting
Prothena Corporation plc has filed a registration statement to register ordinary shares issuable under its Prothena Corporation plc 2018 Long Term Incentive Plan, as amended. The filing incorporates by reference the companys existing public reports, including the Annual Report for the year ended December 31, 2024 and recent quarterly reports, to supply the required disclosure. The companys Constitution, as publicly filed, provides for indemnification of directors and certain executives to the extent permitted by Irish law, and the company maintains insurance and indemnification agreements for officers and directors. The exhibit list documents the Plan and multiple amendments (First through Sixth) and includes legal and auditor consents.
On 28 Jul 2025, Prothena Corporation plc (PRTA) filed a Form 4 reporting that its Chief Scientific Officer, Dr. Wagner M. Zago, acquired 85,000 ordinary shares of the company. The transaction was coded 鈥淎,鈥� indicating an acquisition that was not purchased for cash (reported price $0), consistent with an equity award or similar grant. Following the transaction, Dr. Zago鈥檚 direct beneficial ownership totals 85,000 shares. No derivative securities were reported, and there were no dispositions. The filing was signed by Michael J. Malecek under power of attorney on 30 Jul 2025.
FAQ
What is the current stock price of Prothena (PRTA)?
What is the market cap of Prothena (PRTA)?
